[Immunization against malaria].
Malaria is a great endemic infectious disease, as well as HIV and tuberculosis, responsible world-wide for millions of deaths every year, especially in children. Despite vector control intensification, significant epidemiological improvement and arrival of new and effective antimalarials, malaria remains a major public health issue. The development of a vaccine is still a public health priority because it would considerably modify malaria epidemiology in a relatively near future if associated with vector control and improvement of diagnosis and treatment, in the sixties, several studies have assessed vaccine-candidates targeting different stages of Plasmodium falciparum cycle with different approaches depending on targets. Some aiming a reduction of morbidity and mortality, others a transmission disruption (through vaccine specific of the pre-erythrocytic stage using the circumsporozoite protein with promising phase 3 studies). Other vaccine targets are being studied with hopefully an effective knowledge of the immunological mechanisms.
Service des maladies infectieuses et iropicales, CHU Avicenne, AP-HP, université Paris-13, Bobigny.
Frédéric
F
Méchai
Pierre
P
Loulergue
Olivier
O
Bouchaud
D000818:Animals; D000852:Anopheles / Q000254:growth & development / Q000469:parasitology; D006801:Humans; D008288:Malaria / Q000191:economics / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000138:chemical synthesis / Q000191:economics / Q000627:therapeutic use*; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000191:economics / Q000379:methods; D010963:Plasmodium falciparum / Q000254:growth & development / Q000276:immunology; D014611:Vaccination / Q000191:economics / Q000379:methods
D017780:Malaria Vaccines